Literature DB >> 7914185

High-dose methylprednisolone treatment-induced changes in immunological parameters in progressive MS patients.

A Dufour1, A Salmaggi, L La Mantia, M Eoli, A Nespolo, C Milanese.   

Abstract

The effect of High-Dose Methylprednisolone (HD-MP) treatment on Peripheral Blood (PB) and Cerebrospinal Fluid (CSF) immune parameters was investigated in 9 patients with relapsing-progressive Multiple Sclerosis (MS). Short-time effects included reduction of the percentage of CD3+, CD4+ and CD4+CD45RA+ PB lymphocytes and increase in CD3-CD56+ cells. At the end of the treatment, only increase in PB CD19+ and in CSF CD8+, CD8+CD28+ and decrease of CSF CD4+CD45RA- and serum IL2R levels were observed. No changes in CD11a+CD4+, CD18+CD14+ PB cells were observed after treatment. The results further stress the complex and multifaceted action of HD-MP on immune parameters.

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7914185     DOI： 10.3109/00207459408986295

Source DB:  PubMed          Journal:  Int J Neurosci        ISSN： 0020-7454            Impact factor:   2.292


  3 in total

1.  Treatment with methylprednisolone in relapses of multiple sclerosis patients: immunological evidence of immediate and short-term but not long-lasting effects.

Authors:  E M Martínez-Cáceres; M A Barrau; L Brieva; C Espejo; N Barberà; X Montalban
Journal:  Clin Exp Immunol       Date:  2002-01       Impact factor: 4.330

2.  CD4 subsets (CD45RA/RO) exhibit differences in proliferative responses, IL-2 and gamma-interferon production during intravenous methylprednisolone treatment of multiple sclerosis.

Authors:  A D Crockard; M T Treacy; A G Droogan; S A Hawkins
Journal:  J Neurol       Date:  1996-06       Impact factor: 4.849

3.  ATF2 impairs glucocorticoid receptor-mediated transactivation in human CD8+ T cells.

Authors:  Ling-bo Li; Donald Y M Leung; Matthew J Strand; Elena Goleva
Journal:  Blood       Date:  2007-05-24       Impact factor: 22.113
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.